- Home
- VKTX vs EWTX Comparison
VKTX vs EWTX Comparison
Compare VKTX & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VKTX | EWTX |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VKTX | EWTX |
|---|---|---|
| Price | $29.62 | $36.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $95.86 | $39.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.96 | $12.31 |
| 52 Week High | $43.15 | $40.77 |
Technical Indicators
Market Signals| Indicator | VKTX | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 58.03 |
| Support Level | $29.32 | $27.81 |
| Resistance Level | $36.77 | $39.96 |
| Average True Range (ATR) | 1.25 | 1.76 |
| MACD | 0.04 | 0.44 |
| Stochastic Oscillator | 31.20 | 57.36 |
Price Performance
Historical ComparisonAbout VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.